Premium
Alemtuzumab‐induced Alopecia areata – a case report and systematic literature review of adverse events associated with Alemtuzumab
Author(s) -
Dikeoulia Elsa,
Neufeld Matthias,
Pawlitzki Marc,
Böhm Markus
Publication year - 2021
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.14448
Subject(s) - alopecia areata , alemtuzumab , medicine , dermatology , vitiligo , multiple sclerosis , adverse effect , immunology , antibody
Summary Alemtuzumab is currently approved for the treatment of active relapsing‐remitting multiple sclerosis (RRMS). Despite the efficacy of this therapy several side effects in the skin have been noted during or after infusion including vitiligo, alopecia areata, malignant skin tumors and infections. Awareness of these effects and their treatment is of essential interdisciplinary importance. This minireview provides an overview of the dermatological side effects described in the current literature. We also suggest pathomechanisms underlying these phenomena. To introduce this review, we present the case of a woman with RRMS who developed severe alopecia areata for the first time on alemtuzumab.